TSLA
Tesla
-- 431.660 RGTI
Rigetti Computing
-- 17.0800 NVDA
NVIDIA
-- 137.010 PLTR
Palantir
-- 79.080 LAES
SEALSQ Corp
-- 9.080 
NEWS
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanced design enabling multifunctional immune activation
3. Efficacy independent of typical limitations like tumor neoantigen burden
4. Ability to remodel the tumor microenvironment, transforming 'cold' tumors into 'hot' ones
5. Promising results in nine difficult-to-treat cancers, including microsatellite stable colorectal cancer
This research suggests botensilimab's potential to overcome major challenges in cancer treatment, offering hope to patients with options.
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanced design enabling multifunctional immune activation
3. Efficacy independent of typical limitations like tumor neoantigen burden
4. Ability to remodel the tumor microenvironment, transforming 'cold' tumors into 'hot' ones
5. Promising results in nine difficult-to-treat cancers, including microsatellite stable colorectal cancer
This research suggests botensilimab's potential to overcome major challenges in cancer treatment, offering hope to patients with options.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment